Skip to content

Tbit System Precision and Correlation of Different Blood Samples

A Prospective, Multi-Center, Blood Collection Study to Evaluate TbitTM System Precision and Correlation Between Different Blood Samples Measured With TbitTM System

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04478812
Enrollment
81
Registered
2020-07-21
Start date
2024-09-15
Completion date
2024-11-30
Last updated
2024-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injuries, Traumatic Brain Injury

Brief summary

The Tbit™ System will detect S100B and GFAP concentrations with the blood specimen to produce and compare repeated measures from 3 blood samples from 3 fingersticks from one subject and one 1 venous whole blood sample will be collected from the same subject, on 3 different Tbit™ System by 3 different operators.

Interventions

Tbit™ System will detect S100B and GFAP concentrations with the blood specimen collected

Sponsors

BioDirection Inc
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 18 years of age * Presents to the Emergency Department with suspected traumatic brain injury * Blood sample collected for Tbit™ System within 12 hours of injury * Willing and able to provide informed consent or obtain consent from legal authorized representative (LAR)

Exclusion criteria

* Suspect of ischemic or hemorrhagic stroke with subsequent incidental trauma based on ED examination * Subject suspect of need of craniotomy for the acute trauma for this event * External signs compatible with a depressed skull fracture based on ED exam * Subject requiring administration of blood transfusion after injury and prior to study blood draw * Subject for whom timing of injury is unable to be estimated within 1 hour of certainty * Subject who had neurodegenerative disease or other neurological disorder including dementia, Parkinson's disease, multiple sclerosis, seizures, brain tumors, stroke or TIA within the last 30 days, or history of neurosurgery * Known or suspected to be pregnant * Prisoner or under incarceration * Participating in another clinical research study prior to this study completion

Design outcomes

Primary

MeasureTime frameDescription
Measurement Repeatabilitywithin 12 hours from injury for Tbit and within 30 min from the sample drawn1\. Evaluate the repeatability of measurement of S100B and GFAP concentrations in capillary blood using the Tbit™ System at different clinical sites and between-instrument and between-operator components of variance in the intended use environment.
Compare Measurementswithin 12 hours from injury2\. Compare concentrations of S100B and GFAP measured using Tbit™ System in specimens obtained from a fingerstick blood, venous whole blood, serum and plasma in the intended use environment.

Contacts

Primary ContactLelia A Paunescu, PhD
apaunescu@medicept.com7815268152
Backup ContactTravis Jones, BSc
tjones@medicept.com6783207670

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026